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Balloon mitral valvuloplastyAbstract Aim: We studied the inflammatory status, suggested by high sensitivity C-reactive
protein (hsCRP) in patients with rheumatic mitral stenosis (MS) before, immediately after, and
1-month after balloon mitral valvuloplasty (BMV).
Methods and results: We studied 31 BMV candidates [35.6 ± 12.8 years, 20 (65%) females, and 9
(29%) had atrial fibrillation rhythm]. Mitral valve area (MVA) and hsCRP were measured before,
immediately after BMV, and 1 month after BMV in 13 patients. In addition, hsCRP was measured
in 15 controls. hsCRP was significantly higher in MS patients than control, significantly increased
after BMV, and dropped 1 month after BMV to values comparable to basal but still higher than
normal. hsCRP showed a trend for correlation with MVA after BMV (r= 0.384, p= 0.07), and
the absolute increase in MVA (d-MVA) correlated significantly with the absolute increase in hsCRP
(d-CRP) (r= 0.523, p= 0.01).
21 patients had successful BMV and 10 patients had unsuccessful BMV. The increase in hsCRP post
compared to pre-BMV was attenuated in patients with unsuccessful BMV, and receiver operator
characteristic curve suggested that hsCRP >3.6 before BMV and d-CRP <2.25 mg/dL can detect
patients with unsuccessful BMV with good sensitivities and specificities.
Conclusion: Inflammatory pathogenesis of rheumatic fever, suggested by hsCRP, seems fixed both
before, and after BMV. A basal increase in hsCRP before BMV is related to BMV success and an
acute increase immediately after BMV seems related to trauma of balloon dilatations.
 2016 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The principal cause of mitral stenosis (MS) is rheumatic fever,
which remains endemic, therefore a major public health prob-
lem, in developing countries. Despite the striking decrease in
84 M.A. Abdel Rahman et al.the prevalence of rheumatic fever, MS is still a major problem
for older patients in Western countries.1
Inflammation is a very important part of the mechanism of
development of MS as a squeal of rheumatic fever, and many
studies have shown that inflammatory markers, such as high
sensitivity C-reactive protein (hsCRP), are associated with
the active phase, chronic status, and the progression of rheu-
matic valvular disease.2–4
Percutaneous balloon mitral valvuloplasty (BMV) has
become the standard treatment option for symptomatic
patients with mitral stenosis (MS) who have pliable morphol-
ogy of the mitral valve. The increased clinical applications of
this invasive procedure and cumulative clinical experience have
been accompanied by significant improvements in its success
rate and safety.5,6
C-reactive protein (CRP) is increased in patients with acute
rheumatic fever, and was said to increase during chronic rheu-
matic valvular disease.2,3 The exact natural history of relations
of levels of hsCRP and rheumatic MS with considerations of
treatment with BMV is not yet studied.
The aim of this study was twofold, first, to study the inflam-
matory status, suggested by hsCRP in patients with MS
before, immediately after, and 1-month after BMV, and, sec-
ond, to test the effect of inflammatory status of rheumatic
fever on outcomes of BMV.
2. Methods
The study included 31 consecutive mitral stenosis (MS)
patients who were candidates for balloon mitral valvuloplasty
(BMV) in Ain Shams University hospital. Patients were
excluded if they had any other local or systemic inflammatory
process suspected to increase the basal inflammatory status of
the patients. 13 patients were followed up 1 month after BMV.
All patients studied had their hsCRP measured and echocar-
diography done before, after, and 1 month after BMV. In
addition, 15 age and sex matched control subjects who had
no risk factors and no apparent cause of inflammation had
their hsCRP measured and compared with other study groups.
The Institutional Review Board on Biomedical Research at
Ain-Shams University Hospital, Cairo, Egypt, approved the
study protocol, and all study subjects gave informed consent
consistent with this protocol.
3. Measurement of hsCRP
Venous blood samples were drawn under aseptic conditions
and centrifuged and 2 ml serum was collected and stored at
minus 20 C. All the serum samples were then analyzed for
high sensitivity C-reactive protein (hsCRP) levels at our
pathology department using ELISA technique. CRP was mea-
sured from all patients before and after BMV. hsCRP was also
measured from 13 patients 1 month after BMV and from 15
controls and compared.
4. Echocardiographic studies
Echocardiographic studies were done before and immediately
after BMV, and 1 month after BMV with a commercially avail-
able echocardiography system using a 2.5 MHzmulti-frequencyphased array transducer (Vivid 5; GE Vingmed Ultrasound AS,
Horten, Norway). Mitral valve area was assessed using 2-D
planimetry. The smallest orifice of themitral valvewas identified
by scanning from the left atrium in the direction of the LV apex
using basal-LV short-axis view. The gain settings were adjusted
until the lowest level was determined, atwhich the circumference
of the mitral orifice was still visible. Mitral valve area was calcu-
lated by planimetry of the mitral valve contour after identifica-
tion of the frame with the orifice at its maximal opening in early
diastole.
Mitral valve flow envelope was acquired using continuous
wave Doppler from the mitral position, while keeping the
interrogation line parallel to the color Doppler signal on the
mitral position. The mean transvalvular pressure gradient
was calculated with the modified Bernoulli equation. Two
experienced echocardiographers working separately reviewed
all echocardiographic data, and all measurements were made
in P3 consecutive cardiac cycles and in P5 cycles if the
patient’s rhythm was atrial fibrillation. The average values
were used for the final analyses.
5. Definition of success of BMV
Patients were considered to have successful BMV if they had a
final mitral valve area >1.5 cm2 and a 50% increase in mitral
valve area. Accordingly, patients were classified into patients
with successful BMV and patients with unsuccessful BMV.
6. Statistical analysis
Categorical data were expressed as number (%) and were com-
pared using chi-square test. Continuous data were expressed as
mean ± SD and were compared using student t-test if they
were normally distributed and Mann Whitney U-test if they
were not normally distributed. Normal distribution of the con-
tinuous data was checked using Kolmogorov–Smirnov test.
Correlations were checked for inflammatory markers using
Pearson correlation coefficient. The ability of pre-BMV
hsCRP to predict unsuccessful BMV was checked using recei-
ver operator characteristic curve (ROC-curve), by which the
best cutoff value for prediction that shows best sensitivity
and specificity was checked. One-way ANOVA test was used
to compare different continuous variable before, directly after
and one month after BMV. P-value < 0.05 was considered
statistically significant. All the analyses were performed with
commercially available software (SPSS version 21.0, SPSS,
Inc., Chicago, IL, USA).
7. Results
Table 1 summarizes the demographic and clinical data. The
mean age was 35.6 ± 12.8 years, 20 patients (65%) were
females and 9 patients (29%) had atrial fibrillation rhythm
(Af). 15 patients (48%) had moderate MS and 16 (52%) had
severe MS. 25 patients (81%) had mild mitral regurgitation
(MR), and 6 patients (19%) had moderate MR. After BMV,
MR remained mild in 22 patients (71%), 6 patients had mod-
erate MR (19%) and 3 patients had severe MR (10%).
The mean age of the control subjects was 41 ± 7 and 10
(66.7%) were females. There was no significant difference
Table 2 Comparisons before and after BMV.
Before After p-value
LAP (mmHg) 27.8 ± 6.3 15.4 ± 5.9 <0.001
RVSP (mmHg) 52.6 ± 17 38.2 ± 11 0.007
RAP (mmHg) 10 ± 4 9 ± 4.1 0.46
PG (mmHg) 12.2 ± 6.7 5.7 ± 2.6 <0.001
LAV (ml) 125.3 ± 40 112 ± 35 0.26
RAV (ml) 55.6 ± 32 50 ± 31.7 0.57
MVA (cm2) 0.98 ± 0.27 2.03 ± 0.55 <0.001
hsCRP (mg/dL) 3.98 ± 1.9 6.5 ± 2.3 <0.001
LAP, left atrial pressure, RVSP, right ventricular systolic pressure,
RAP, right atrial pressure, PG, mean pressure gradient across
mitral valve, LAV, left atrial volume, RAV, right atrial volume,
MVA, mitral valve area and hsCRP, high sensitivity C-reactive
protein.
Table 1 Demographics and basic data.
Variable (n= 31)
Age (years) 35.6 ± 12.8
Male/female n(%) 11(35)/20(65)
Sinus/atrial fibrillation n(%) 22(71)/9(29)







Continuous variables are expressed as mean ± SD and categorical
variables are expressed as n(%). MS, mitral stenosis and MR,
mitral regurgitation.
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(p= 0.886).
8. MVA and hsCRP after BMV and at 1-month follow-up
Table 2 summarizes the pressures, echocardiographic data and
inflammatory markers before and after BMV. In addition,
Wilkin’s echocardiographic score for all patients before
BMV was 6.3 ± 0.9.
As expected, MVA and PG increased significantly after
compared to before BMV (Table 2). One month after BMV,
it was found that MVA and PG did not significantly change
compared to those after BMV while MVA remained signifi-
cantly higher and PG remained significantly lower than their
corresponding values before BMV (Table 3). Interestingly,
hsCRP significantly increased after compared to before BMV
(Table 2, Fig. 1), and it was found that hsCRP values at one
month dropped significantly compared to after BMV, however
was not different than their values before BMV (Table 3,
Fig. 1). Compared to controls, the basal hsCRP before BMV
was significantly higher. After 1 month from BMV, hsCRP
continued to be higher than controls (Table 3, Fig. 1).
While MVA significantly increased After BMV, significant
decrease was noticed for LAP, RVSP, and PG. There was no
significant difference in case of RAP, LAV or RAV.9. Comparisons according to success of BMV
21 (66%) patients were shown to have had sufficient dilatation
of their mitral valve and were considered successful, and 10
(33%) patients were considered to have had unsuccessful pro-
cedures due to insufficient dilatation. Table 4 summarizes com-
parisons between patients with and without successful BMV.
Before BMV, there was no significant difference between
patients with successful versus non-successful BMV regarding
LAP, MVA, or CRP. After BMV, there was no significant dif-
ference between patients with successful versus non-successful
BMV regarding LAP, or CRP, while d-CRP was significantly
lower in patient with unsuccessful BMV (3.5 ± 2.3 vs. 1.4
± 1.6 mg/dL, p= 0.041).
It is important to note that, as expected from the classifica-
tion, patients with successful BMV had significantly higherMVA after BMV and higher d-MVA (1.25 ± 0.4 vs. 0.34
± 0.22 cm2, p=<0.001).
It is also worth noting that, both patients with successful
and unsuccessful BMV, had their LAP significantly decreased,
and MVA significantly increased. As for hsCRP, values signif-
icantly increased after compared to before BMV only in
patients with successful BMV, while this increase was attenu-
ated in unsuccessful cases.
10. Correlations with inflammatory markers and prediction of
success of BMV
A trend of correlation for hsCRP with MVA after BMV was
noticed (r= 0.384, p= 0.07), while there was no correlation
before BMV (r= 0.022, p= 0.912). Interestingly, d-CRP
showed a significant correlation with d-MVA (r= 0.523,
p= 0.01).
Receiver operator characteristic curves (ROC-curves) for
values that best detect unsuccessful BMV were initiated for
pre-BMV hsCRP and for d-CRP. ROC-curves suggested that
CRP before BMV >3.6 and d-CRP <2.25 mg/dL, could pre-
dict unsuccessful BMV with sensitivities of 78% and 86% and
specificities of 72% and 63% (Fig. 2).
11. Discussion
Our study demonstrated that:
1. hsCRP is increased in patients with rheumatic MS. Further
increase occurs immediately after BMV, which decreases
back again after 1 month to values comparable to their cor-
responding before BMV, however was still considered
higher than normal.
2. Higher levels of hsCRP before BMV and less increase in
hsCRP after BMV are predictive of unsuccessful
procedures.
12. Inflammation in the course of natural history of MS
The most accepted hypothesis to explain the valvular damage
in acute rheumatic fever is based upon an antigenic similarity
Table 3 Comparisons for inflammatory markers after 1 month follow-up.
Control Before After 1 month p-value
MVA – 0.98 ± 0.27 2.03 ± 0.55 2.02 ± 0.65 <0.001*
PG – 12.2 ± 6.7 5.7 ± 2.6 5.2 ± 2.8 <0.001**
hsCRP (mg/dL) 1.5 ± 0.7 3.98 ± 1.9 6.5 ± 2.3 3.5 ± 1.5 <0.001***
Continuous variables are expressed as mean ± SD and categorical variables are expressed as n(%). MVA, mitral valve area, PG, mean Doppler
derived pressure gradient and hsCRP, high sensitivity C-reactive protein.
* p= 0.962 between 1 month and after BMV, p< 0.001 between 1 month and before BMV.
** p= 0.992 between 1 month and after BMV, p= 0.005 between 1 month and before BMV.
*** p< 0.001 between 1 month and after BMV, p= 0.841 between 1 month and before BMV, <0.001 between controls and before BMV,
<0.001 between controls and after BMV, 0.027 between controls and 1 month after BMV.
Figure 1 Comparisons of hsCRP between controls and patients
before, after and 1 month after BMV.
86 M.A. Abdel Rahman et al.between human heart valves and group A beta hemolytic
streptococci that causes abnormal antibody response leading
to an autoimmune process, which causes damage to the heart
valves, most commonly a stenotic mitral valve.7–9
Our study showed that, compared to controls, patients with
chronic MS had significantly high levels of hsCRP, which sup-
ports the previous claim of an ongoing inflammatory process
as a part of the pathogenesis of MS.6,10,11 It was not surprising,
however, to have the levels of hsCRP significantly elevated
immediately after BMV, because the nature of the procedure
itself is traumatic and should cause an increased level of acute
phase reactants, especially when more trauma, and thus more
dilatation, is exerted. This procedural trauma–inflammation
relationship was proven in our study by the direct correlation
between the d-CRP and d-MVA, which means that, the moreTable 4 Comparisons before and after BMV according to success
Successful BMV (n= 21)
Before After p
LAP (mmHg) 27.4 ± 7 14.6 ± 6 <
MVA (cm2) 0.96 ± 0.29 2.2 ± 0.4 <
CRP (mg/dL) 3.7 ± 1.9 6.9 ± 2.3 <
Abbreviations as in Table 3.the trauma exerted by balloon dilatations, the larger MVA in
comparison with its value before BMV, but also the higher the
circulating levels of hsCRP because of trauma.
Interestingly, levels of hsCRP after 1 month fell back to
values comparable to their correspondents before BMV, which
are still higher than normal.
It is reasonable to suspect that, this continuing increase in
hsCRP during follow-up is an indicator of the chronic status
of inflammation of rheumatic heart disease. Thus, despite that
stenosis itself might be alleviated, the valve might be still sub-
ject to the same pathophysiological mechanism that originally
caused the stenosis. The expected consequence of that later in
life would be occurrence of mitral valve restenosis. We have
previously reported the relation between the status of ongoing
inflammation and the development of mitral valve restenosis
for patients studied in the long follow-up after BMV.12 In this
study, despite patients were not followed up to check for devel-
opment of restenosis, a possible evidence of the ongoing
inflammation that might lay the foundation for the develop-
ment of restenosis is found. According to the conclusion of
our previous report, only those patients who show a further
increase in inflammatory markers would develop restenosis,
and thus patients of our current study should be followed up
before suspicion of restenosis is made.
13. Role of hsCRP in prediction of success after BMV
In our study, two variables related to hsCRP were found to
predict the occurrence of unsuccessful procedure. The first
one was high hsCRP before BMV, and the second one was
the less increase in hsCRP after BMV. According to the defini-
tion used in our study, unsuccessful procedure was the one
with outcomes suggestive of failure to sufficiently dilate the
mitral valve. In our point of view, the two variables explainof procedure.
Unsuccessful BMV
Before After p
0.001 29.8 ± 6 18.8 ± 4 0.003
0.001 0.98 ± 0.3 1.3 ± 0.22 0.04
0.001 4.6 ± 1.8 5.9 ± 2.4 0.351
Figure 2 Receiver operator characteristic curve for d-CRP
(dashed black line) and hsCRP before BMV (solid red line) for
detection of successful BMV.
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different perspectives. Higher basal hsCRP might suggest a
severer basal inflammatory process. If so, valves subjected to
such state of inflammation might have developed more fibrosis
and thus became more difficult to sufficiently increase in size in
response to balloon dilatation. A supporting evidence for that
was the reported correlation with Wilkin’s echo score and
hsCRP before BMV. Moreover, less increase in hsCRP after
BMV, might signify, less effort exerted during balloon dilata-
tion, thus suggesting, again, the relation of traumatic effect
of BMV to dilatation of the mitral valve and release of inflam-
matory markers.
It is important to note that, the predictive role of pre-BMV
levels of hsCRP is a confirmation of a previous report that
showed similar result.13
14. Limitations
The study suffered some important limitations. First, the study
included a small number of patients, a lot of whom were lost
during follow-up. Thus further studies should confirm the cur-
rent study findings using a larger number of patients. Second,
it seems more appropriate to study patients before BMV, and
to follow them up for development of restenosis after BMV.
Because this would be extremely time consuming, future
prospective long-term follow-up studies should test the effects
of the found ongoing inflammatory process on development of
mitral valve restenosis. Third, the study was only concerned
with the anatomical status of the mitral valve post BMV and
1 month after BMV; thus, further studies should also focus
on the effects of ongoing inflammation on the clinical picture
immediately after BMV and at follow-up.15. Conclusion
Inflammatory process linked to pathogenesis of rheumatic
fever, suggested by hsCRP, seems fixed both before, and after
BMV. A basal increase in hsCRP before BMV is related to
BMV procedural success and an acute increase immediately
after BMV seems related to trauma exerted by balloon dilata-
tions, which, at short term, falls back to values that are still
higher than normal thus suggesting ongoing pathogenic effects
of rheumatic fever on the mitral valve even after BMV.
Conflict of interest
Author states that there is no conflict of interest.
References
1. Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Barwolf C,
Levang OW, et al. A prospective survey of patients with valvular
heart disease in Europe: the Euro heart survey on valvular heart
disease. Eur Heart J 2003;24:1231–43.
2. Yegin O, Coskun M, Ertug H. Cytokines in acute rheumatic fever.
Eur J Pediatr 1997;156:25–9.
3. Karthikeyan G, Thachil A, Sharma S, Kalaivani M, Ramakrish-
nan L. Elevated high sensitivity CRP levels in patients with mitral
stenosis and left atrial thrombus. Int J Cardiol 2007;122:252–4.
4. Chen MC, Chang HW, Wu CJ, Yang CH, Yu TH, Chen CJ, et al.
Balance between plasma levels of tumor necrosis factor-alpha and
interleukin-10 in rheumatic mitral stenosis. Cardiology
2005;104:171–5.
5. Ben Farhat M, Ayari M, Maatouk F, Betbout F, Gamra H, Jarra
M, et al. Percutaneous balloon versus surgical closed and open
mitral commissurotomy: seven-year follow-up results of a ran-
domized trial. Circulation 1998;97:245–50.
6. Carabello BA. Modern management of mitral stenosis. Circulation
2005;112:432–7.
7. McCarty M. Nature of rheumatic fever. Circulation
1956;14:1138–43.
8. Wannamaker LW. Differences between streptococcal infections of
the throat and of the skin (second of two parts). N Engl J Med
1970;282:78–85.
9. Wannamaker LW. The chain that links the heart to the throat.
Circulation 1973;48:9–18.
10. Narin N, Kutukculer N, Ozyurek R, Bakiler AR, Parlar A,
Arcasoy M. Lymphocyte subsets and plasma IL-1 alpha, IL-2, and
TNF-alpha concentrations in acute rheumatic fever and chronic
rheumatic heart disease. Clin Immunol Immunopathol
1995;77:172–6.
11. Sharma V, Stewart RA, Zeng I, Raffel C, Kerr AJ. Comparison of
atrial and brain natriuretic peptide for the assessment of mitral
stenosis. Heart Lung Circ 2011;20:517–24.
12. Rifaie O, Omar AM, Abdel-Rahman MA, Raslan H. Does a
chronic inflammatory state have a role in the development of
mitral restenosis after balloon mitral valvuloplasty? Int J Cardiol
2014;172:e417–418.
13. Krasuski RA, Bush A, Kay JE, Mayes Jr CE, Wang A, Fleming J,
et al. C-reactive protein elevation independently influences the
procedural success of percutaneous balloon mitral valve commis-
surotomy. Am Heart J 2003;146:1099–104.
